<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03378973</url>
  </required_header>
  <id_info>
    <org_study_id>2017-1304</org_study_id>
    <nct_id>NCT03378973</nct_id>
  </id_info>
  <brief_title>The Effects of Dexmedetomidine Dose on Motor Evoked Potentials</brief_title>
  <official_title>The Effects of Dexmedetomidine Dose on Motor Evoked Potentials During Spine Surgery: A Randomized, Single-blind Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital for Special Surgery, New York</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital for Special Surgery, New York</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This a parallel group, two-arm, randomized superiority trial that will compare the effect of
      two different doses of dexmedetomidine on motor evoked potentials during spine surgery
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This a parallel group, two-arm, randomized superiority trial that will compare the effect of
      two different doses of dexmedetomidine on suitability of motor evoked potentials for
      intraoperative monitoring during spine surgery
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>The anesthesiologist administering anesthetic agents will have knowledge of their doses. The technologist performing motor evoked potential testing and other participants will not.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of patients with monitorable of motor evoked potentials</measure>
    <time_frame>During a single surgery</time_frame>
    <description>Monitorable is defined as stable signals being present in 3 muscles in each lower extremity, with mean peak-to-peak amplitude of at least 50 uV, and with mean-normalized interquartile variability of 0.9 or less.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Spinal Fusion</condition>
  <arm_group>
    <arm_group_label>High dose dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive dexmedetomidine 0.5 mcg/kg/hr plus propofol 50 mcg/kg/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose dexmedetomidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive dexmedetomidine 1.0 mcg/kg/hr plus propofol 25 mcg/kg/min</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Patients will randomly assigned to received Arm 1 anesthesia or Arm 2 anesthesia during surgery.</description>
    <arm_group_label>High dose dexmedetomidine</arm_group_label>
    <arm_group_label>Low dose dexmedetomidine</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing multi-level posterior spine fusions requiring motor evoked
             potential monitoring

        Exclusion Criteria:

          -  Allergy to dexmedetomidine, propofol

          -  Conditions knows to make recording of motor evoked potentials difficult, including
             poorly controlled diabetes, severe peripheral neuropathy, severe myelopathy, or
             previous surgery during which motor evoked potentials were difficult to obtain

          -  Hepatic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Emerson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital for Special Surgery, New York</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ronald Emerson, MD</last_name>
    <phone>212-774-2742</phone>
    <email>emersonr@hss.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronald Emerson, MD</last_name>
      <phone>212-774-2742</phone>
      <email>emersonr@hss.edu</email>
    </contact>
    <investigator>
      <last_name>Ronald Emerson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2017</study_first_submitted>
  <study_first_submitted_qc>December 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2017</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>motor evoked potentials</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

